Skip to main content

Table 2 Primary outcomes, overall and by condition (95% uncertainty interval)

From: Bridging the gap: an economic case study of the impact and cost effectiveness of comprehensive healthcare intermediaries in rural Mexico

Condition

# Treated

Mean QALYs gained

Mean cost per QALY (USD, PPP)

Discount factor

 

0%

3%

0%

3%

All

69

14.4 (12.4–15.8)

6.3 (5.2–7.2)

383 (262–588)

488 (339–747)

Skin cancer

11

3.8 (2.5–5.3)

3.0 (2.0–4.1)

513 (371–781)

583 (421–889)

Cataract

13

2.0 (1.3–2.8)

1.2 (0.8–1.8)

1284 (809–1995)

1506 (949–2339)

 Severe

5

4.4 (3.1–6.3)

2.6 (1.8–3.7)

591 (420–850)

713 (507–1025)

 Moderate

8

0.4 (0.3–0.7)

0.3 (0.2–0.6)

1717 (1051–2711)

2001 (1225–3160)

Hernia

6

30.3 (28.9–32.1)

9.9 (8.9–11.1)

31 (27–36)

63 (55–73)

 Severe

2

15.7 (14.0–17.9)

9.6 (8.3–11.2)

66 (54–80)

86 (69–107)

 Moderate

4

37.7 (36.4–39.2)

10.0 (9.3–11.0)

14 (13–14)

52 (47–56)

Heart conditions

6

26.7 (26.1–27.4)

9.1 (8.7–9.7)

51 (44–61)

137 (116–165)

 Severe

4

29.6 (29.1–30.1)

10.1 (9.6–10.7)

40 (39–40)

113 (108–119)

 Moderate

2

20.8 (20.2–21.9)

7.1 (6.8–7.7)

67 (50–93)

173 (129–234)

Epilepsy

8

24.5 (21.3–26.9)

8.9 (6.9–10.4)

44 (41–53)

103 (90–134)

 Severe

5

20.0 (16.8–21.4)

8.8 (6.8–10.0)

63 (58–77)

137 (121–180)

 Less severe

3

32.0 (28.8–36.0)

9.0 (7.2–11.2)

13 (12–14)

46 (37–58)

Gall bladder conditions

4

26.2 (23.5–29.2)

11.2 (9.5–13.2)

17 (16–19)

41 (35–47)

Cholecystitis

3

29.2 (26.0–32.7)

12.5 (10.5–14.9)

15 (14–17)

36 (30–43)

Cholelithiasis

1

17.2 (16.2–18.4)

7.3 (6.6–8.1)

23 (21–25)

54 (49–60)

Thyroid conditions

4

7.0 (4.5–9.4)

3.8 (2.5–5.2)

56 (42–88)

100 (74–157)

Kidney stones

6

4.0 (2.7–5.6)

2.1 (1.4–2.9)

304 (218–444)

568 (407–830)

Breast cancer

5

29.9 (29.8–30.0)

18.4 (18.3–18.6)

77 (77–78)

124 (123–124)

Cryptorchidism

6

13.6 (5.4–13.6)

6.0 (2.4–6.0)

57 (57–144)

129 (129–324)